Does one size fit all? Drug resistance and standard treatments: Results of six tuberculosis programmes in former Soviet countries

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 10, 2005, Pages 1147-1154

  Bonnet, Maryline ^a   Sizaire, V ^b   Kebede, Y ^c   Janin, A ^d   Doshetov, D ^e   Mirzoian, B ^f   Arzumanian, A ^g   Muminov, T ^h   Iona, E ⁱ   Rigouts, L ^j   Rusch Gerdes S ^k   Varaine, F ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b MSF   (Belgium)

^c MSF   (Netherlands)

^d MSF International   (Switzerland)

^e TB Dispensary   (Uzbekistan)

^f TB Dispensary   (Azerbaijan)

^g TB Hospital   (Georgia)

^h Almaty University of Energy and Communication   (Kazakhstan)

ⁱ ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^j INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^k National Mycobacterial Reference Laboratory   (Germany)

more..

Author keywords

Drug resistance; Eastern Europe; Treatment outcomes; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; CHEMOTHERAPY; DRUG SENSITIVITY; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PRISON; RETROSPECTIVE STUDY; REVIEW; RUSSIAN FEDERATION; SHORT COURSE THERAPY; SMEAR; STANDARD; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; USSR;

ANTITUBERCULAR AGENTS; CONFIDENCE INTERVALS; DIRECTLY OBSERVED THERAPY; FEMALE; HUMANS; MALE; ODDS RATIO; PREVALENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; USSR;

EID: 26444594247     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Raviglione M C, Rieder H L, Styblo K, Khomenko A G, Esteves K, Kochi A. Tuberculosis trends in Eastern Europe and the former UUSR. Int J Tuberc Lung Dis 1994; 75: 400-416.
2. Mawer C, Ignatenko N V, Wares D F, et al. Comparison of the effectiveness of WHO short-course chemotherapy and standard Russian antituberculous regimens in Tomsk, Western Siberia. Lancet 2001; 358: 445-449.
3. World Health Organization. Global tuberculosis control surveillance, planning, financing. Report 2003. WHO/CDS/TB/ 2003.316. Geneva, Switzerland: WHO, 2003.
4. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no 2: Prevalence and Trends. WHO/CDS/ TB/2000.278. Geneva, Switzerland: WHO, 2000.
5. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. WHO/CDS/TB/2003.1313. Geneva, Switzerland: WHO, 2003.
6. Bass J B Jr, Farer L S, Hopewell P C, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149: 1359-1374.
7. Escalante P, Graviss E A, Griffith D E, Musser J M, Awe R J. Treatment of isoniazid-resistant tuberculosis in southeastern Texas. Chest 2001; 119: 1730-1736.
8. Gupta R, Raviglione M C, Espinal M, Arnadottir T. Guideline for establishing DOTS-plus pilot projects for the management of multi-drug-resistant tuberculosis (MDR-TB). WHO/CDS/ TB/2000.279. Geneva, Switzerland: WHO, 2000.
9. Veen J, Raviglione M, Rieder H L, et al. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J 1998; 12: 505-510.
10. Rieder H, Chonde T M, Myking H, et al. The Public Health Service National Tuberculosis Reference Laboratory and the National Laboratory Network. Paris, France: International Union Against Tuberculosis and Lung Disease, 1998.
11. Espinal M A. The global situation of MDR-TB. Tuberculosis 2003; 83: 44-51.
12. Coninx R, Pfyffer G E, Mathieu C, et al. Drug resistant tuberculosis in prisons in Azerbaijan: case study. BMJ 1998; 316: 1423-1425.
13. Pfyffer G E, Strässle A, Van Gorkum T, et al. Multidrug-resistant tuberculosis in prison inmates, Azerbaijan. Emerg Infect Dis 2001; 7: 855-861.
14. Lambert M L, Hasker E, Van Deum A, Robefroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 2003; 3: 282-287.
15. Shafer R W, Singh S P, Larkin C, Small P M. Evidence of exogenous reinfection and mixed infection with more than one strain of Mycobacterium tuberculosis among Spanish HIV-infected inmates. AIDS 1999; 13: 615-620.
16. Yeh R W, Hopewell P C, Daley C L. Simultaneous infection with two strains of Mycobacterium tuberculosis identified by restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 1999; 3: 537-539.
17. Warren R M, Victor T C, Streicher E M, et al. Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med 2004; 169: 610-614.
18. Santha T, Garg R, Frieden T R, et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000. Int J Tuberc Lung Dis 2002; 6: 780-788.
19. Kritski A L, Rodrigues de Jesus L S, Andrade M K, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997; 111: 1162-1167.
20. Farmer P, Kim J Y. Community based approaches to the control of multidrug-resistant tuberculosis: introducing 'DOTS-plus'. BMJ 1998; 317: 671-674.
21. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
22. De Lourdes Garcia-Garcia M, Ponce-De-Leon A, Garcia-Sancho M C, et al. Tuberculosis-related deaths within a well-functioning DOTS control program. Emerg Infect Dis 2002; 8: 1327-1333.
23. Barnes P F, Leedom J M, Chan L S, et al. Predictors of short-term prognosis in patients with pulmonary tuberculosis. J Infect Dis 1988; 158: 366-371.
24. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
25. Grzybowski S, Enarson D. Results in pulmonary tuberculosis patients under various treatment program conditions. Bull Int Union Tuberc 1978; 53: 70-75.
26. Lan N T N, Iadermarco M F, Binkin N J, Tung L B, Quy H T, Co N V. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2001; 5: 575-578.
27. Migliori G B, Espinal M, Danilova I D, Punga V V, Grzemska M, Raviglione M C. Frequency of recurrence among MDR-TB cases 'successfully' treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis 2002; 6: 858-864.
28. Freeman M C, Bayona J, Shin S S, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4: 108-114.
29. Van Deun A, Salim A H, Rigouts L, Rahman M, Fissette K, Portaels F. Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases. Int J Tuberc Lung Dis 2001; 5: 329-338.
30. Toungoussova O S, Nizovsteva N I, Mariandyshev A O, et al. Impact of drug-resistant Mycobacterium tuberculosis on treatment outcome of culture-positive cases of tuberculosis in the Archangel Oblast, Russia, in 1999. Eur J Clin Microbiol Infect Dis 2004; 23: 174-179.
31. Singla R, Al-Sharif N, Al-Sayegh M O, et al. Influence of antituberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia. Int J Tuberc Lung Dis 2002; 6: 585-591.
32. Van Deun A, Salim H A, Kumar Das A P, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8: 560-567.